Impact of treatment with TransCon PTH on Quality of Life, cognitive function, brain structure, and cerebral capillary bloodflow in patients with hypoparathyroidism
Phase 4 – monitoring after market approval
Conditions:
Hypoparathyroidism
Sponsor: Region Midtjylland
trial.available_in:
БГ
Overview
Trial status: Authorised
Correlation between cognitive impairment measured by neuropsychological assessment and capillary transit time heterogeneity, cortical blood volume and hemodynamic parameters., Status of cognitive function in PTH treated compared to conventional treated controls, Difference in groups in size of structures in the brain.
Difference in microvascular hemodynamic between PTH- and conventionally treated patients with chronic HypoPT
Description
Correlation between cognitive impairment measured by neuropsychological assessment and capillary transit time heterogeneity, cortical blood volume and hemodynamic parameters., Status of cognitive function in PTH treated compared to conventional treated controls, Difference in groups in size of structures in the brain.
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 40 participants
Interventions
Alfacalcidol Stada 1 micrograme capsule moi
Drug
Yorvipath 168 micrograms/0.56 mL solution for injection in pre‑filled pen
БГ